العلاج الجهازي لسرطان الخلايا الكبدية المتقدم (المرحلة C وفق BCLC) مع تشمع كبدي Child-Turcotte-Pugh A

References

DOI: 10.1097/HEP.0000000000000466

• Systemic therapy should be offered to patients with preserved liver function (Child-Turcotte-Pugh A or well-selected Child-Turcotte-Pugh B cirrhosis), ECOG PS 0-1, who have BCLC Stage C HCC, or BCLC Stage B HCC not amenable to or progressing after locoregional therapy (Level 1, Strong Recommendation).
• AASLD advises second-line therapy in patients with preserved liver function (Child-Turcotte-Pugh A or well-selected Child-Turcotte-Pugh B cirrhosis), ECOG PS 0-1, who develop HCC progression or intolerance with first-line systemic therapy (Level 1, Strong Recommendation).
• AASLD advises sorafenib or lenvatinib as preferred agents after first-line atezolizumab plus bevacizumab if patients are not eligible for clinical trials (Level 5, Weak Recommendation).
• Cabozantinib, regorafenib, or ipilimumab plus nivolumab may be used in these patients (Level 5, Weak Recommendation).